Revue des maladies respiratoires最新文献

{"title":"Sommaire","authors":"","doi":"10.1016/S0761-8425(24)00217-1","DOIUrl":"https://doi.org/10.1016/S0761-8425(24)00217-1","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 6","pages":"Page iii"},"PeriodicalIF":0.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0761842524002171/pdfft?md5=8d49a0aee6cc7216ae5748edbc0e98fe&pid=1-s2.0-S0761842524002171-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Case report of a cystic lung disease: From a rarity to the discovery of an unknown genetic variant].","authors":"L-A Deflandre, T Weber, M Ote, P Bourgeois","doi":"10.1016/j.rmr.2024.04.002","DOIUrl":"10.1016/j.rmr.2024.04.002","url":null,"abstract":"<p><strong>Introduction: </strong>Cystic lung diseases are rare, with numerous differential diagnoses. Iconographic discovery consequently necessitates medical examinations in view of proposing an etiological orientation.</p><p><strong>Case report: </strong>A 57-year-old woman consulted in pulmonology following fortuitous detection of a cystic lung disease on an abdominal CT scan. Complementary medical examinations did not allow orientation towards a particular diagnosis. During a follow-up consultation, the patient informed her pulmonologist of the recent detection of a monoallelic variant of a FAT4 gene in one of her daughters, who was suffering from edema of the lower limbs secondary to a disease of the lymphatic system. As our patient had a similar history, she likewise received a genetic analysis. A monoallelic variant not described in the genetic databases was observed, and considered as a probable pathogenic variant (class 4/5 on the pathogenicity scale of genetic variants).</p><p><strong>Conclusion: </strong>After analyzing the available literature data, we raise questions about a possible link between this variant of the FAT4 gene, chronic lymphedema and our patient's cystic lung disease.</p>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":"439-445"},"PeriodicalIF":0.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"À propos d’un cas clinique de maladie kystique pulmonaire : d’une rareté à la découverte d’un variant génétique inconnu","authors":"L.-A. Deflandre ,&nbsp;T. Weber ,&nbsp;M. Ote ,&nbsp;P. Bourgeois","doi":"10.1016/j.rmr.2024.04.002","DOIUrl":"10.1016/j.rmr.2024.04.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Les maladies kystiques pulmonaires sont rares, avec de nombreux diagnostics différentiels. Leur découverte iconographique implique donc la réalisation d’examens complémentaires afin de proposer une orientation étiologique.</p></div><div><h3>Observation</h3><p>Une femme âgée de 57 ans a consulté en pneumologie suite à la découverte fortuite d’une maladie kystique pulmonaire sur un scanner de l’abdomen. Les différents examens complémentaires réalisés chez la patiente n’ont pas permis l’orientation vers un diagnostic en particulier. Lors d’une consultation de suivi, la patiente a informé son pneumologue de la récente mise en évidence d’un variant mono-allélique du gène <em>FAT4</em> chez une de ses filles, atteinte d’œdème des membres inférieurs secondairement à une maladie du système lymphatique. Notre patiente ayant des antécédents similaires, elle a pu bénéficier également d’une analyse génétique. Un variant mono-allélique non décrit dans les bases de données génétiques a été observé et considéré comme un variant probablement pathogène (classe 4/5 sur l’échelle de pathogénicité des variants génétiques).</p></div><div><h3>Conclusion</h3><p>Après analyse des données disponibles de littérature, nous nous interrogeons sur l’existence d’un lien entre ce variant du gène <em>FAT4</em>, le lymphœdème chronique et la maladie kystique pulmonaire, mis en évidence chez notre patiente.</p></div><div><h3>Introduction</h3><p>Cystic lung diseases are rare, with numerous differential diagnoses. Iconographic discovery consequently necessitates medical examinations in view of proposing an etiological orientation.</p></div><div><h3>Case report</h3><p>A 57-year-old woman consulted in pulmonology following fortuitous detection of a cystic lung disease on an abdominal CT scan. Complementary medical examinations did not allow orientation towards a particular diagnosis. During a follow-up consultation, the patient informed her pulmonologist of the recent detection of a monoallelic variant of a <em>FAT4</em> gene in one of her daughters, who was suffering from edema of the lower limbs secondary to a disease of the lymphatic system. As our patient had a similar history, she likewise received a genetic analysis. A monoallelic variant not described in the genetic databases was observed, and considered as a probable pathogenic variant (class 4/5 on the pathogenicity scale of genetic variants).</p></div><div><h3>Conclusion</h3><p>After analyzing the available literature data, we raise questions about a possible link between this variant of the <em>FAT4</em> gene, chronic lymphedema and our patient's cystic lung disease.</p></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 6","pages":"Pages 439-445"},"PeriodicalIF":0.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141044028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposition aux pesticides et maladies respiratoires chroniques","authors":"N. Jestin-Guyon ,&nbsp;C. Raherison-Semjen","doi":"10.1016/j.rmr.2024.03.004","DOIUrl":"10.1016/j.rmr.2024.03.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Les pesticides sont utilisés dans le monde entier, principalement dans le domaine agricole, afin de lutter contre des organismes nuisibles et protéger les récoltes. Cependant, l’ensemble de la population mondiale y est finalement exposé (consommation de fruits et légumes, vivre à proximité de champs traités, etc.) à des degrés de toxicité variés.</p></div><div><h3>État des connaissances</h3><p>Les études épidémiologiques ont contribué à l’identification de familles chimiques de pesticides entraînant des effets sur la santé humaine (troubles cognitifs, maladie de Parkinson, cancer de la prostate, etc.) dont la santé respiratoire. Les niveaux de preuve scientifiques actuels mettent en cause l’implication de substances actives insecticides, herbicides et fongicides en lien avec des maladies chroniques respiratoires, comme la bronchopneumopathie chronique obstructive (BCPO) chez les professionnels exposés ou encore les sifflements évocateurs d’asthme chez les enfants exposés en période prénatale et postnatale.</p></div><div><h3>Perspectives</h3><p>La prévention et la sécurité des individus exposés sont de réels enjeux de santé publique, ainsi que l’identification des familles chimiques de pesticides ayant des effets sur la santé respiratoire des populations concernées.</p></div><div><h3>Conclusions</h3><p>L’exposition environnementale et professionnelle aux pesticides provoque l’apparition de troubles et de symptômes respiratoires.</p></div><div><h3>Introduction</h3><p>Pesticides are used worldwide, mainly in agriculture as a means of controlling pests and protecting crops. That said, the entire world population is ultimately subject to pesticide exposure (consumption of fruits and vegetables, living near treated fields…), with varying degrees of toxicity involved.</p></div><div><h3>State of the art</h3><p>In recent decades, epidemiological studies have contributed to the identification of chemical pesticide families with detrimental effects on human health: cognitive disorders, Parkinson's disease, prostate cancer… and impairment in respiratory functioning. Current scientific evidence points to the implication of the active substances in insecticides, herbicides and fungicides in chronic respiratory diseases, two examples being chronic obstructive pulmonary disease (COPD) in exposed workers, and asthmatic wheezing in children during prenatal or postnatal exposure.</p></div><div><h3>Perspectives</h3><p>The safety of individuals exposed to pesticides is of key importance in public health. Further epidemiological investigations are needed to identify the chemical families affecting certain populations.</p></div><div><h3>Conclusions</h3><p>The scientific literature suggests strong links between pesticide exposure and respiratory health. Whether it be environmental or occupational, pesticide exposure can lead to respiratory disorders and symptoms of varying severity.</p></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 5","pages":"Pages 343-371"},"PeriodicalIF":0.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effets indésirables des biothérapies de l’asthme sévère","authors":"G. Dargentolle ,&nbsp;M. Georges ,&nbsp;G. Beltramo ,&nbsp;C. Poisson ,&nbsp;P. Bonniaud","doi":"10.1016/j.rmr.2024.04.001","DOIUrl":"10.1016/j.rmr.2024.04.001","url":null,"abstract":"<div><h3>Introduction</h3><p>L’asthme reste sévère et mal contrôlé pour 4 % des patients. L’identification de multiples mécanismes physiopathologiques a permis l’essor de biomédicaments, désormais au nombre de 5 disponibles en France, avec un profil de sécurité plutôt rassurant mais restant encore incertain devant le manque de recul en vraie vie pour les nouvelles molécules.</p></div><div><h3>État des connaissances</h3><p>Les effets indésirables des biothérapies sont variés mais restent majoritairement bénins. Observées sous ces différents traitements, les céphalées, les douleurs articulaires, les réactions cutanées au site d’injection, la fièvre et l’asthénie sont fréquentes. Les complications ophtalmologiques semblent concerner exclusivement le dupilumab, avec des kératites et conjonctivites chez les patients traités pour une dermatite atopique. On observe des complications respiratoires, s’agissant essentiellement de pharyngites ou d’infections respiratoires hautes. Une hyperéosinophilie parfois majeure peut survenir sous dupilumab, nécessitant de rechercher un retentissement systémique ou une vascularite. Les réactions allergiques sont rares. Une surveillance rapprochée lors des premières injections parait nécessaire.</p></div><div><h3>Conclusion</h3><p>Les biothérapies de l’asthme sévère sont des médicaments récents avec un profil de tolérance favorable, bénéficiant cependant de peu de recul en vie réelle, justifiant une surveillance accrue des prescripteurs.</p></div><div><h3>Introduction</h3><p>Asthma is a pathology that remains severe and is inadequately controlled in 4% of patients. Identification of multiple pathophysiological mechanisms has led to the development of biomedicines, of which there are currently five available in France, with a safety profile that appears favorable but remains uncertain due to a lack of real-life experience with these new molecules.</p></div><div><h3>State of knowledge</h3><p>Although relatively benign, the adverse effects of biologics are diverse. Headache, joint pain, skin reactions at the injection site, fever and asthenia are commonly observed during the different treatments. Ophthalmological complications seem restricted to dupilumab, with numerous cases of keratitis and conjunctivitis in patients with atopic dermatitis. Several respiratory complications have also been observed, essentially consisting in pharyngitis and other upper respiratory infections. Hypereosinophilia may occur, mainly with dupilumab, requiring investigation of systemic repercussions or vasculitis. Allergic reactions are uncommon but require careful monitoring during initial injections.</p></div><div><h3>Conclusion</h3><p>Biologics for severe asthma are recent drugs with a favorable safety profile, but with little real-life experience, justifying increased vigilance by prescribing physicians.</p></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 5","pages":"Pages 372-381"},"PeriodicalIF":0.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Principaux messages de la deuxième Biennale BPCO 2023 de la SPLF. Le patient au cœur du parcours de soins","authors":"J. Ancel ,&nbsp;E. Chen ,&nbsp;A. Pavot ,&nbsp;L. Regard ,&nbsp;O. Le Rouzic ,&nbsp;M. Guecamburu ,&nbsp;M. Zysman ,&nbsp;A. Rapin ,&nbsp;C. Martin ,&nbsp;T. Soumagne ,&nbsp;M. Patout ,&nbsp;N. Roche ,&nbsp;G. Deslee","doi":"10.1016/j.rmr.2024.03.008","DOIUrl":"10.1016/j.rmr.2024.03.008","url":null,"abstract":"<div><h3>Introduction</h3><p>La deuxième Biennale BPCO organisée par le groupe de travail BPCO de la Société de pneumologie de langue française (SPLF) a eu lieu à Paris (Cochin) le 13 décembre 2023.</p></div><div><h3>État des connaissances</h3><p>Les grandes tendances 2023 en termes de concepts, définitions, thérapeutiques nouvelles, parcours de soins et les situations complexes d’infections respiratoires, les comorbidités cardiovasculaires et les modalités d’oxygénothérapie et ventilation ont été discutées.</p></div><div><h3>Perspectives</h3><p>Les évolutions majeures intègrent les concepts de pré-BPCO et d’étiotypes, les trajectoires et les nouvelles définitions des exacerbations. Les résultats récents sur les biothérapies permettent d’envisager des options pharmacologiques nouvelles. Les évaluations du parcours de soins en France soulignent les difficultés actuelles. La réadaptation respiratoire constitue un élément thérapeutique majeur insuffisamment utilisé. Les infections respiratoires nécessitent une évaluation rigoureuse. L’évaluation et le traitement des comorbidités cardiovasculaires et de l’hypertension pulmonaire sont essentielles. Les modalités d’oxygénothérapie et de ventilation ont évolué, permettant d’envisager des traitements plus adaptés.</p></div><div><h3>Conclusions</h3><p>Une approche personnalisée apparaît primordiale, en plaçant le patient au cœur du parcours de soins et en coordonnant les différents acteurs de santé autour de la BPCO.</p></div><div><h3>Introduction</h3><p>The second COPD Biennial organized by the COPD working group of the French Society of Respiratory Diseases took place in Paris (Cochin) on 13th December 2023.</p></div><div><h3>State of the art</h3><p>Major trends in 2023 were discussed; they encompassed concepts, definitions, biologics, care pathways, pulmonary rehabilitation and complex situations entailed by respiratory infections, cardiovascular comorbidities and pulmonary hypertension, and modalities of oxygen therapy and ventilation.</p></div><div><h3>Perspectives</h3><p>The different talks underlined major changes in COPD including the concepts of pre-COPD, etiotypes, health trajectories and new definitions of exacerbation. Recent results in biologics for COPD open the door to new pharmacological options. Assessment of current care pathways in France highlighted some causes for concern. For example, pulmonary rehabilitation is a key but insufficiently practiced element. Respiratory infections require careful assessment and treatments. Diagnosis and treatment of cardiovascular comorbidities and pulmonary hypertension are of paramount importance. As of late, oxygen therapy and ventilation modalities have evolved, and are beginning to afford more personalized options.</p></div><div><h3>Conclusions</h3><p>As regards COPD, a personalized approach is crucial, placing the patient at the center of the care pathway and facilitating coordination between healthcare providers.</p></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 5","pages":"Pages 331-342"},"PeriodicalIF":0.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140760452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0761-8425(24)00198-0","DOIUrl":"https://doi.org/10.1016/S0761-8425(24)00198-0","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 5","pages":"Page iii"},"PeriodicalIF":0.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0761842524001980/pdfft?md5=0d65542561f4e810e0d18d5da5e74900&pid=1-s2.0-S0761842524001980-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deuxième biennale BPCO de la Société de pneumologie de langue française 2023 : des mutations majeures","authors":"G. Deslée ,&nbsp;O. Le Rouzic ,&nbsp;M. Zysman ,&nbsp;N. Roche","doi":"10.1016/j.rmr.2024.03.007","DOIUrl":"10.1016/j.rmr.2024.03.007","url":null,"abstract":"","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 5","pages":"Pages 329-330"},"PeriodicalIF":0.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140772874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Place de l’endoscopie dans la gestion des nodules pulmonaires périphériques, partie 2 : traitement","authors":"S. Lachkar ,&nbsp;F. Guisier ,&nbsp;E. Dantoing ,&nbsp;L. Thiberville ,&nbsp;M. Salaün","doi":"10.1016/j.rmr.2024.03.006","DOIUrl":"10.1016/j.rmr.2024.03.006","url":null,"abstract":"<div><p>Si la découverte de nodules pulmonaires périphériques est devenue un problème majeur en pratique oncologique, leur diagnostic apparaît aujourd’hui accessible aux techniques d’endoscopie avancée. Ces techniques permettent également de guider le traitement de ces nodules. Dans cette deuxième partie, nous détaillerons comment les techniques d’endoscopie avancée peuvent aider le traitement chirurgical par le biais d’un marquage préopératoire, d’une part, et le traitement par radiothérapie stéréotaxique par le biais de la pose de marqueur fiduciaire, d’autre part. Enfin nous aborderons comment elles pourront, dans un futur proche, également participer à l’ablation endoscopique de ces nodules.</p></div><div><p>The management of peripheral lung nodules is challenging, requiring specialized skills and sophisticated technologies. The diagnosis now appears accessible to advanced endoscopy (see Part 1), which can also guide treatment of these nodules; this second part provides an overview of endoscopy techniques that can enhance surgical treatment through preoperative marking, and stereotactic radiotherapy treatment through fiduciary marker placement. Finally, we will discuss how, in the near future, these advanced endoscopic techniques will help to implement ablation strategy.</p></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 5","pages":"Pages 390-398"},"PeriodicalIF":0.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140782316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ventilation non invasive dans l’insuffisance respiratoire aiguë des patients d’onco-hématologie : quelle place en 2023 ?","authors":"J. Mayaux,&nbsp;M. Decavele,&nbsp;M. Dres,&nbsp;M. Lecronier,&nbsp;A. Demoule","doi":"10.1016/j.rmr.2024.03.005","DOIUrl":"10.1016/j.rmr.2024.03.005","url":null,"abstract":"&lt;div&gt;&lt;p&gt;L’insuffisance respiratoire aiguë (IRA) est la première cause d’admission des patients porteurs d’une néoplasie active en réanimation. De sévérité variable, l’IRA des patients d’onco-hématologie relève également d’étiologies variées, cependant largement dominées par les pneumonies aiguës infectieuses (IRA hypoxémique de novo) opportunistes ou non, et les décompensations de pathologies cardiorespiratoires (ex. œdème aigu pulmonaire ou décompensation de bronchopneumopathie chronique obstructive). Chez ces patients, le recours à l’intubation orotrachéale est associé à un doublement du risque de mortalité à l’hôpital. Par conséquent, au cours des trois dernières décennies de nombreux travaux de recherche ont tenté d’argumenter et de mieux définir la place de la ventilation non invasive (VNI) dans le contexte spécifique de l’IRA du patient d’onco-hématologie. Si les bénéfices de la VNI dans la prise en charge de l’œdème pulmonaire aigu ou de situations d’hypoventilation alvéolaire (IRA hypercapnique) sont bien démontrés, son positionnement dans l’IRA hypoxémique de novo est débattu et a été récemment remis en question. Dans les années 2000, à la suite de publication d’essais randomisés contrôlés, la VNI était recommandée en première ligne de traitement. Le recours à la VNI permettait notamment de réduire le recours à l’intubation orotrachéale chez ces patients. Dans les dernières études randomisées, le bénéfice de la VNI sur la survie ou le recours à l’intubation orotrachéal n’est plus observé. La VNI n’est désormais plus recommandée dans la prise en charge de l’IRA hypoxémique de novo du patient d’onco-hématologie.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p&gt;Acute respiratory failure (ARF) is a leading cause, along with sepsis, of admission to the intensive care unit (ICU) of patients with active cancer. Presenting variable clinical severity, ARF in onco-hematological patients has differing etiologies, primarily represented by possibly opportunistic acute infectious pneumonia (de novo hypoxemic ARF), and decompensation in chronic cardiac or respiratory diseases (e.g., acute pulmonary edema or exacerbated chronic obstructive pulmonary disease). In these patients, orotracheal intubation is associated with a doubled risk of in-hospital mortality. Consequently, over the last three decades, numerous researchers have attempted to demonstrate and pinpoint the precise role of non-invasive ventilation (NIV) in the specific context of ARF in onco-hematological patients. While the benefits of NIV in the management of acute pulmonary edema or alveolar hypoventilation (hypercapnic ARF) are well-demonstrated, its positioning in de novo hypoxemic ARF is debatable, and has recently been called into question. In the early 2000s, based on randomized controlled trials, NIV was recommended as first-line treatment, one reason being that it allowed significantly reduced use of orotracheal intubation. In the latest randomized studies, however, the benefits of NIV in terms of survival orotrac","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"41 5","pages":"Pages 382-389"},"PeriodicalIF":0.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}